Home > News > Second- and Third-line Treatment in Advanced Non-small-cell Lung Cancer
Lung Cancer
Read Time: 2 mins

Second- and Third-line Treatment in Advanced Non-small-cell Lung Cancer

Published Online: June 3rd 2011 European Oncology, 2009;5(1):38-40 DOI: https://doi.org/10.17925/EOH.2009.05.1.38
Authors: Adolfo Favaretto, Giulia Pasello
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. About 50% of patients present with locally advanced or metastatic disease. First-line therapy usually consists of a combination of cisplatin or carboplatin with a third-generation agent (paclitaxel, docetaxel, gemcitabine or vinorelbine) that results in less than 5% five-year survival. In recent years advances in second- and third-line treatment have led to a prognostic improvement. Two cytotoxic agents, docetaxel and pemetrexed, are approved in NSCLC second-line treatment, and a new class of drugs against specific molecular targets – tyrosine kinase inhibitors – has emerged as an alternative to conventional treatment. Many trials are ongoing to assess the activity of new drugs, alone or in association, or new combinations of third-generation chemotherapeutic agents.

Article:

Non-small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. About 50% patients present with locally advanced or metastatic disease, and their five-year survival amounts to less than 5%.1 First-line chemotherapy in advanced NSCLC usually consists of a combination of cisplatin or carboplatin with a thirdgeneration agent (paclitaxel, docetaxel, gemcitabine or vinorelbine). About 30% of patients treated in first-line with one of these combinations achieve a response lasting for four to five months. For a long period the results of second-line treatment of advanced NSCLC were disappointing in terms of both response rate and survival.

Single-agent Chemotherapy
Docetaxel (Taxotere®, sanofi-aventis) as second-line treatment was the first drug to show in phase III trials an advantage in survival and quality of life (QoL) compared with best supportive care (BSC) (TAX 317)2 and with single-agent treatment with ifosfamide (Ifex®, Bristol- Myers Squibb Co.) or vinorelbine (Navelbine®, Pierre Fabre Pharmaceuticals) (TAX 320).3 The better toxicity profile with the weekly compared with the three-weekly schedule was shown in the TAX 320 trial and confirmed in many randomised clinical trials and two meta-analyses,4,5 with no significant differences in survival. Recently, the multitarget antifolate agent pemetrexed (Alimta®, Eli Lilly and Co.) demonstrated a similar clinical response to and a better safety profile than docetaxel in second-line treatment of NSCLC patients. Both agents provided a median survival of about eight months, one-year survival of 30% and a response rate of 10%, with less haematological toxicity in the pemetrexed arm.6 Due to its good toxicity profile, even elderly and performance status (PS) 3 patients, for whom the American Society of Clinical Oncology (ASCO) guidelines contraindicate any chemotherapy, could benefit from pemetrexed.7,8 Histology is an important factor in treatment selection in both firstand second-line treatment with pemetrexed, due to the different expression of thymidylate synthase (TS) between adenocarcinoma and squamous cell carcinoma. A retrospective analysis of the data ofthe pemetrexed versus docetaxel phase III study indicated that the squamous cell subgroup patients treated with docetaxel had statistically better survival than patients treated with pemetrexed. Conversely, in the non-squamous subgroup pemetrexed was statistically superior to docetaxel.9 Among third-generation cytotoxic agents, gemcitabine (Gemzar®, Eli Lilly and Co.) and paclitaxel showed promising activity and acceptable toxicity profile as single agents in the second-line treatment of advanced NSCLC.10,11 Some patients seem to benefit more than others from second-line treatment with paclitaxel (e.g. patients with stable disease after a first-line platinumbased therapy, or a longer time to relapse). Table 1 shows some meaningful phase III trials performed in recent years.

To read full article please click here

Article Information:

Further Resources

Share this Article
Related Content In Lung Cancer
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72